Incidence and HR of SSSI
| Result | nbDMARD n=3673 | All anti-TNF n=11881 | Etanercept n=4139 | Infliximab n=3475 | Adalimumab n=4267 |
|---|---|---|---|---|---|
| Follow-up (pyrs) | 5416 | 17048 | 6122 | 4529 | 6397 |
| SSSI events | 39 | 269 | 120 | 79 | 67 |
| SSSI incidence (/100 patient-years) | 0.7 (0.5–1.0) | 1.6 (1.4–1.8) | 2.0 (1.6–2.3) | 1.7 (1.4–2.2) | 1.0 (0.8–1.3) |
| SSSI unadjusted HR | Ref | 2.1 (1.5–3.0) | 2.8 (1.9–4.0) | 2.5 (1.7–3.7) | 1.5 (1.0–2.2) |
| SSSI adjusted HR* | Ref | 1.3 (0.8–2.2) | .5 (0.9–2.5) | 1.5 (0.9–2.5) | 1.1 (0.6–2.1) |
↵* Adjusted rates using propensity modelling described in the Methods section and using multiple imputations to replace missing baseline variables.
nbDMARD, non-biological disease-modifying antirheumatic drug; SSSI serious skin and soft tissue infections; TNF, tumour necrosis factor.